Investor optimism for Eli Lilly 's diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer…
#elililly #club #sp #mounjaro #jimcramer #ytd #sp500 #zepbound #novonordisk #danish
Continue reading...